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Background
Cognitive improvement has been reported in patients receiving
centrally acting angiotensin-converting enzyme inhibitors
(C-ACEIs).
Aims
To compare cognitive decline and survival after diagnosis
of Alzheimer’s disease between people receiving C-ACEIs,
non-centrally acting angiotensin-converting enzyme inhibitors
(NC-ACEIs), and neither.
Method
Routine Mini-Mental State Examination (MMSE) scores were
extracted in 5260 patients receiving acetylcholinesterase
inhibitors and analysed against C-/NC-ACEI exposure at the
time of Alzheimer’s disease diagnosis.
Results
In the 9 months after Alzheimer’s disease diagnosis, MMSE
scores significantly increased by 0.72 and 0.19 points per year
in patients on C-ACEIs and neither respectively, but
deteriorated by 0.61 points per year in those on NC-ACEIs.
There were no significant group differences in score
trajectories from 9 to 36 months and no differences in survival.
Conclusions
In people with Alzheimer’s disease receiving acetylcholinesterase
inhibitors, those also taking C-ACEIs had stronger initial
improvement in cognitive function, but there was no evidence
of longer-lasting influence on dementia progression.
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As hypertension is associated with both an increased incidence of
dementia,1 and conversion from mild cognitive impairment to
dementia,2 attention has focused on treatments for hypertension
as modifiers of cognitive decline. The influence of a number of
antihypertensives has been investigated from mild cognitive
impairment2,3 through to established dementia,4 with some agents
associated with a lowered risk, but negative or inconsistent results
from clinical trials.5–9 Angiotensin-converting enzyme inhibitors
(ACEIs) have attracted interest in Alzheimer’s disease specifically;
however, not all ACEIs cross the blood–brain barrier which may
give rise to heterogeneity in effects. In one study of community
residents, reduced cognitive decline was found in those receiving
centrally active inhibitors (centrally acting angiotensin-converting
enzyme inhibitors (C-ACEIs)) compared with non-centrally active
inhibitors (non-centrally acting angiotensin-converting enzyme
inhibitors (NC-ACEIs)) and calcium channel blockers.10 Studies
of dementia incidence have been mixed,11–15 but C-ACEI receipt
was associated with slower cognitive decline in dementia over 6
months,4 and C-ACEIs have recently been recommended for
slowing dementia progression in elderly patients with hyperten-
sion.16 Given the paucity of evidence in this field, we analysed a
large, prospective clinical database of people receiving dementia
assessment and acetylcholinesterase treatment, to compare cogni-
tive function trajectories and survival among C-ACEI users with
those using NC-ACEIs or neither agent.
Method
Study setting and data source
A retrospective observational study was conducted using data
from the South London and Maudsley NHS Foundation Trust
(SLaM) Biomedical Research Centre (BRC) case register. SLaM is
one of Europe’s largest mental healthcare providers, serving a
geographic catchment of over 1.2 million residents in four South
London boroughs (Lambeth, Lewisham, Southwark and Croydon).
In 2007–2008, the Clinical Record Interactive Search (CRIS) appli‐
cation was developed with National Institute for Health Research
(NIHR) funding to provide researcher access to anonymised copies
of SLaM’s electronic health record within a robust governance
framework.17 The SLaM BRC case register has been described in
detail,18 and has supported a range of studies,19,20 including several
longitudinal studies of large dementia cohorts.21–23 Data are cur‐
rently archived in CRIS on over 270 000 cases with a range of
mental disorders and the database has full approval for secondary
analysis (Oxford Research Ethics Committee C, reference 08/
H0606/71+5). Data from CRIS have been extensively supple‐
mented through natural language processing applications using
Generalised Architecture for Text Engineering (GATE) software,
applying information extraction techniques to derive structured
information from the extensive text fields held in the mental health
record.24
Sample
All cases with Alzheimer’s disease (ICD-10 F00.x) diagnosed at
any point between 1 January 2000 and 31 May 2014 were
ascertained in CRIS using a combination of data from structured
fields for primary and secondary diagnoses, and a specific natural
language processing application extracting text associated with
diagnostic statements in open text fields.24 The sample was
restricted to patients who received a first diagnosis of Alzheimer’s
disease during the study period, and who were commenced
on treatment with an acetylcholinesterase inhibitor. Those
who received angiotensin receptor blockers at the time of
Alzheimer’s disease diagnosis were also excluded – this was partly*These authors contributed equally to this work.
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to maximise homogeneity of the sample and partly because those
receiving this treatment had the most routine data on cognitive
decline.
Measurements
The index date for defining exposure and confounding vari‐
ables was the date of the first recorded Alzheimer’s disease
diagnosis. Demographic information obtained included age at
diagnosis, age at death, gender, ethnicity (European and non-
European) and index of multiple deprivation (2010 projections
from the UK Census) for each patient’s neighbourhood (UK
lower super output area) at the time of diagnosis. Health of
the Nation Outcome Scales (HoNOS) are routinely administered
in UK mental health services and recorded as structured data
on the electronic health record. HoNOS item scores and dates
were extracted for the period of 6 months before and after the
diagnosis date, and the closest scores in time were included in
analyses.
Medications received were extracted from structured medi‐
cation fields supplemented by natural language processing
applications applied to open text fields.24 C-ACEIs were defined
as perindopril, ramipril, trandolapril, captopril, fosinopril, lisino-
pril, prinivil, monopril; NC-ACEIs were defined as enalapril,
imidapril, cilazapril, quinapril, moexipril. Initial and most recent
dates were ascertained for when these medications were recorded,
and exposure was defined on the basis of recorded medication
use at or before the Alzheimer’s disease diagnosis. The analysis
excluded patients who were recorded as receiving both C-ACEIs
and NC-ACEIs (because these groups were too small to analyses
separately), and a third group of patients were defined with no
recorded ACEI use. Use of antipsychotic or antidepressant medi‐
cation was also ascertained at the time of the Alzheimer’s
disease diagnosis. Use of other antihypertensive medication
(vasodilators, diuretics, calcium channel blockers, beta-blockers,
alpha-blockers) was also ascertained at the time of Alzheimer’s
disease diagnosis.
The primary outcome was change in cognitive function
as estimated from recorded Mini-Mental State Examination
(MMSE) scores. In British dementia treatment services, cognitive
function continues to be primarily monitored in routine clinical
practice using the MMSE, a 30-point measure of global function
in wide use.25 MMSE numerator and denominator scores and
dates of assessment for the cohort were obtained from structured
fields and a bespoke natural language processing application.24
According to the availability of follow-up data and to minimise
the influence of differential attrition, MMSE scores were restricted
to those recorded within 3 years after the Alzheimer’s disease
diagnosis date, and the analysed sample was restricted to patients
with more than one MMSE score recorded. Date of death was
obtained from death registry information from the Office for
National Statistics (ONS) linked to CRIS.
Statistical analysis
Initially, generalised additive models for location, scale and shape
(GAMLSS)26 were used to visualise the shape of MMSE score
trajectories for the three cohorts – those who were receiving
C-ACEIs, those who were receiving NC-ACEIs and those who
were not receiving any ACEIs. An advantage of GAMLSS is that
they are not restricted to a linearity assumption: important
because of the potential association between cognitive decline
and time since Alzheimer’s disease diagnosis and acetylcholines-
terase inhibitor initiation. GAMLSS are parametric, in that they
require a parametric distribution assumption for the response vari‐
able, and ‘semi’ in the sense that the modelling of the parameters
of the distribution, as functions of explanatory variables, may
involve using non-parametric smoothing functions. Although
GAMLSS output provided a helpful way of visualising the pattern
of cognitive decline within the observation window, it did not
permit analyses of predictive covariates, confounding and effect
modification. By inspecting the curves derived from GAMLSS, it
was concluded that it would be appropriate to use parametric
methodology in the form of a two-piecewise linear mixed model
to estimate cognitive change and its predictors, using the two time
components: Segment 1 for the 0–9 months after diagnosis and
Segment 2 for the 9–36 months after diagnosis. Slopes and slope
differences were obtained using linear mixed estimation metho-
dology. Two-piecewise model estimates were adjusted for age,
gender, ethnicity, other antihypertensives, antipsychotic, antide-
pressant receipt and HoNOS subcomponents including agitated
behaviour, self-injury, problem drinking or drug use, physical
illness, hallucinations or delusions, depressed mood, relationship
problems, daily living problems, living conditions problems and
occupational problems.
Survival analyses were carried out for mortality as an outcome
up to a census point of 8 July 2014. Kaplan–Meier survival curves
were constructed using STATA 13 software, and a log-rank test
was carried out to test associations with ACEI use.
Results
Fourteen patients were excluded who were receiving both C-ACEI
and NC-ACEI agents and an additional ten patients who had
only one recorded MMSE score since diagnosis. Furthermore,
27 patients receiving C-ACEIs, 2 patients receiving NC-ACEIs and
296 patients receiving neither were excluded as they received
angiotensin receptor blockers at the time of Alzheimer’s disease
diagnosis. The analysed samples comprised 1207 patients receiving
C-ACEIs, 143 receiving NC-ACEIs and 3910 receiving neither.
Characteristics of the samples are summarised in Table 1. In
summary, the group receiving NC-ACEIs were more likely to
be to be male, to be of non-European ethnicity and to be rated as
having hallucinations or delusions than those receiving C-ACEIs
or neither. There were no significant individual group differences
in age (ANOVA post hoc test). However, a post hoc test showed
a significant difference in mean deprivation score between
C-ACEI group and the group receiving neither ACEI (P=0.008)
and between the NC-ACEI group and those receiving neither
ACEI (P=0.041). Antipsychotic and antidepressant uses were
more common in patients receiving C-ACEIs. Both the C-ACEI
and NC-ACEI groups were rated as having more severe phy‐
sical health problems on the HoNOS than those receiving
neither. Importantly, although there were differences in the
timing and number of some measurement points, there was no
difference in MMSE score closest to diagnosis between the three
groups.
Figure 1 displays GAMLSS curve for trajectories of MMSE
scores by ACEI receipt, and Tables 2 and 3 summarise the results
of the linear mixed estimations from two-piecewise estimations
model comapring slopes at 0–9 months and 9–36 months after
Alzheimer’s disease diagnosis. Analysis with adjustments showed
the NC-ACEI group to have slightly higher MMSE scores at
Alzheimer’s disease diagnosis compared with the other two groups.
In patients who received C-ACEIs, MMSE scores improved over
the first 9 months, with a slope coefficient of 0.72 (points per
year), whereas they declined in those receiving NC-ACEIs and
slightly improved in those that received neither ACEI, with slope
coefficients of −0.61 and 0.19 respectively. For patients receiving
C-ACEIs, these slopes were significantly different both compared
with those receiving NC-ACEIs (slope difference 1.33, P=0.028)
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and compared with those who received neither ACEI (slope
difference 0.53, P=0.037). However, there were no significant
group differences in slopes for the 9–36 month period after
diagnosis. Figure 2 displays GAMLSS curve for trajectories of
MMSE scores by other antihypertensive use for those who did not
receive any ACEIs. There were no significant differences in slopes
between those who received other antihypertensive medication
and not receiving such medication. Likewise, as shown in Fig. 3,
there was no observable group difference in survival. Log-rank
tests for equality of survivor functions gave P-values of 0.82
and 0.84, respectively, for comparisons between C-ACEIs and
NC-ACEIs, and between C-ACEIs and no ACEI.
Table 1 Sample characteristics at/around Alzheimer's disease diagnosis by exposure status
Variable
C-ACEIs only
(n=1207)
NC-ACEIs only
(n=143)
Neither agent
(n=3910) Pa
Mean age at diagnosis (s.d.), years 80.5 (7.1) 81.4 (7.0) 80.2 (8.0) 0.116
Age at diagnosis, n (%) 0.095
<65 27 (2.2) 1 (0.7) 170 (4.3)
65–69 62 (5.1) 7 (4.8) 177 (4.5)
70–74 130 (10.8) 15 (11) 420 (10.7)
75–79 266 (22.0) 22 (15.1) 735 (18.8)
80–84 329 (27.3) 49 (33.6) 1021 (26.1)
85–89 280 (23.2) 29 (20.5) 892 (22.8)
90 and over 113 (9.4) 20 (14.4) 495 (12.7)
Age at death, n (%) 0.127
<65 1 (0.1) 0 (0) 24 (0.6)
65–69 7 (0.6) 0 (0) 26 (0.7)
70–74 22 (1.8) 3 (2.7) 83 (2.1)
75–79 73 (6.0) 7 (4.8) 201 (5.1)
80–84 134 (11.1) 15 (10.3) 433 (11.1)
85–89 151 (12.5) 23 (16.4) 583 (14.9)
90 and over 145 (12.0) 22 (15.1) 594 (15.2)
Alive at end of follow-up, n (%) 674 (55.8) 73 (50.7) 1966 (50.3) 0.013
Ethnicity, n (%) <0.001
European 961 (79.6) 109 (76.0) 3270 (83.6)
Non-European 246 (20.4) 34 (24.0) 640 (16.4)
Gender, n (%) 0.009
Male 442 (36.6) 55 (38.4) 1301 (33.3)
Female 765 (63.4) 88 (61.6) 2609 (66.7)
Mean (s.d.) index of multiple deprivation 27.1 (11.2) 28.1 (11.2) 26.0 (11.2) <0.001
Mean ACE inhibitors follow-up years (s.d.) 0.8 (1.5) 1.1 (1.8) 0.024
Medications received, n (%)
Antihypertensives 617 (51.1) 80 (55.9) 1684 (43.1) <0.001
Antipsychotics 328 (27.2) 39 (27.3) 995 (25.4) 0.884
Antidepressants 459 (38.0) 48 (33.6) 1261 (32.3) 0.695
MMSE scores, mean (s.d.)
Score closest to diagnosis 19.0 (6.3) 19.9 (6.9) 19.1 (6.5) 0.71
Number of MMSE scores per patient 4.6 (3.8) 4.7 (4.1) 4.0 (3.6) <0.001
Interval between diagnosis and MMSE
score closest to diagnosis, yearsb
0.0 (0.7 ) −0.1 (0.7) −0.1 (0.8) 0.033
Interval between first mention of an
ACE inhibitor and diagnosis, yearsc
−0.1 (1.7) −0.5 (2.0) 0.041
Mean (s.d.) HoNOS subscale score
Agitated behaviour 0.7 (1.0) 0.7 (1.0) 0.7 (1.0) 0.652
Self-injury 0.1 (0.4) 0.1 (0.3) 0.1 (0.3) 0.481
Problem drinking/drug use 0.1 (0.4) 0.1 (0.3) 0.1 (0.4) 0.248
Cognitive problems 2.4 (0.8) 2.4 (0.8) 2.4 (0.9) 0.937
Physical illness 1.6 (1.1) 1.6 (1.2) 1.4 (1.2) <0.001
Hallucinations/delusions 0.4 (0.9) 0.5 (0.9) 0.4 (0.8) 0.367
Depressed mood 0.6 (0.8) 0.6 (0.8) 0.6 (0.8) 0.289
Other mental problems 0.8 (1.0) 0.8 (1.0) 0.8 (1.0) 0.287
Relationship problems 0.6 (0.9) 0.7 (0.9) 0.6 (0.9) 0.281
Daily living problems 1.8 (1.1) 1.8 (1.1) 1.7 (1.2) 0.843
Living conditions problems 0.4 (0.8) 0.5 (0.9) 0.4 (0.8) 0.609
Occupational problems 1.1 (1.1) 1.2 (1.1) 1.0 (1.1) 0.143
Mean (s.d.) interval between HoNOS and diagnosis, years 0.1 (0.6) 0.2 (0.7) 0.2 (0.8) 0.082
C-ACEIs, centrally acting angiotensin converting enzyme inhibitors; NC-ACEIs, non-centrally acting angiotensin converting enzyme inhibitors; MMSE, Mini-Mental State Examination;
ACE, angiotensin converting enzyme; HoNOS, Health of the Nation Outcome Scales.
a. Difference in means between three groups tested using one-way ANOVA test, difference in means between two medication groups were tested using independent sample t-tests,
differences in frequencies tested using chi-squared tests.
b. Negative values indicating that MMSE scores recorded before Alzheimer’s disease diagnosis.
c. Negative values indicating ACE inhibitor medication recorded before Alzheimer’s disease diagnosis.
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Discussion
In what we believe to be the largest investigation to date of
antihypertensive agents and dementia progression, we compared
trajectories of routinely measured cognitive function between
patients receiving C-ACEIs and NC-ACEIs at the time of
Alzheimer’s disease diagnosis and those receiving neither type of
medication. An initial improvement in cognitive function was
found in patients receiving C-ACEIs over the first 9 months after
diagnosis compared with deteriorations in the NC-ACEIs group.
However, there was no evidence of longer-term slope differences
and no differences in survival between the groups.
As previously summarised, several studies have suggested that
C-ACEIs may influence cognitive function trajectories in people
without dementia. The Cardiovascular Health Study Cognition
Sub-Study, which followed up people with hypertension for 6
years, found no significant differences in cognitive decline between
ACEIs and other antihypertensives, but did find significantly
reduced cognitive decline in people receiving C-ACEIs: reduced
by 65% per year of exposure in this group compared with those
receiving NC-ACEIs.11 A Japanese study found no difference in
Alzheimer’s disease incidence associated with antihypertensive
drugs as a whole, but did find a significantly lower risk in a
subgroup analysis of captopril and perindopril (C-ACEIs) com-
pared with enalapril and imidapril (NC-ACEIs).13 Also, in secon‐
dary analyses of the Perindopril Protection Against Recurrent
Stroke Study (PROGRESS), there was a reduced risk of cognitive
decline in the treatment group.27 There has been less investigation
of associations between ACEIs and dementia progression, although
one study found that C-ACEIs, compared with other antihyper-
tensive drugs, were associated with a reduced rate of cognitive
decline in hypertensive patients with mild to moderate Alzheimer’s
disease, although all participants had stable and comparable blood
pressure levels,10 suggesting a mechanism other than lowered blood
pressure. Our findings of initial improvement in cognition function
in patients with C-ACEIs are also consistent with findings from two
smaller research cohorts of reduced 12-month functional decline in
patients with Alzheimer’s disease,28,29 with reduced 6-month
cognitive decline in patients with Alzheimer’s, vascular and mixed
dementia,21 and with reduced cognitive decline in patients with
Alzheimer’s disease with specific ACE haplotypes.9
The mechanisms by which C-ACEIs might influence dementia
outcomes remain unclear. As previously described, ACEIs have
been highlighted as potentially detrimental for cognitive function
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Fig. 1 Comparison of longitudinal change in Mini-Mental State Examination (MMSE) in the samples using generalised additive models for location,
scale and shape (GAMLSS) methodology. ACE, angiotensin converting enzyme.
Table 2 Adjusted MMSE slopes (points/year) after Alzheimer's disease diagnosis comparing those who received C-ACEIs and those who
did not receive any ACEI
MMSE slope Received C-ACEI
Did not receive
ACEI
MMSE slope difference
(MMSE per year)
P for group
difference
First MMSE slope 0–9 months 0.72 (0.89 to 0.55) 0.19 (0.12 to 0.21) 0.53 (0.05 to 1.01) 0.037
Second MMSE slope 9–36 months −0.81 (−1.17 to −0.45) −0.68 (−1.54 to 0.18) −0.13 (−1.03 to 0.77) 0.626
MMSE, Mini-Mental State Examination; C-ACEIs, centrally acting angiotensin converting enzyme inhibitors; ACEI, angiotensin converting enzyme inhibitor.
Table 3 Adjusted MMSE slopes (points/ year) after Alzheimer's disease diagnosis comparing those who received C-ACEIs and those who
received NC-ACEIs
MMSE slope Received C-ACEIs Received NC-ACEIs
MMSE slope difference
(MMSE per year)
P for group
difference
First MMSE slope 0–9 months 0.72 (0.89 to 0.55) −0.61 (−0.21 to −1.02) 1.33 (0.25 to 1.41) 0.028
Second MMSE slope 9–36 months −0.81 (−1.17 to −0.45) −0.63 (−1.36 to 0.10) −0.18 (−1.50 to −1.14) 0.531
MMSE, Mini-Mental State Examination; C-ACEIs, centrally acting angiotensin converting enzyme inhibitors; NC-ACEIs, non-centrally acting angiotensin converting enzyme inhibitors.
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because of ACE degrading amyloid and observations of an increase
of Aβ1-42 inmice associated with ACEI administration.30 However,
there are also a number of potential reasons why these agents may
be protective. First, reduced cerebral blood flow has been observed
in Alzheimer’s disease,31 and C-ACEIs may improve this by
inhibiting the production of angiotensin II, a vasoconstrictor; this
is supported by perivascular staining of both angiotensin II and
ACE seen in patients with Alzheimer’s disease.32 Second, the renin
angiotensin system within the brain has an effect on neural
plasticity and long-term potentiation,33 and it has been proposed
that C-ACEIs through preventing activation of this system inhibits
the release of inflammatory cytokines which may be involved in the
neurodegenerative process.34,35 The renin angiotensin aldosterone
system (RAAS) acts throughout the body, including the central
nervous system,36 and there is growing evidence of its importance in
neurodegenerative disorders including Alzheimer’s disease and
Parkinson’s disease.37 Perindopril, but not other ACEIs, signifi-
cantly inhibited hippocampal ACE, preventing cognitive im‐
pairment in mouse models of Alzheimer’s disease,38,39 and a study
in hypertensive rats found that lifelong treatment with captopril
(C-ACEI) significantly reduced impairment in learning and memory
compared with hydralazine, despite equal blood pressure control in
both groups.40 Third, angiotensin II inhibits release of acetylcho-
line,41 and C-ACEIs might increase acetylcholine activity (and thus
improve cognitive function) by reducing angiotensin II levels.11
Yamada et al demonstrated an enhancing effect of perindopril
(C-ACEI) on extracellular acetylcholine levels in the perirhinal cortex
in rats with chronic cerebral hypoperfusion.42
The fact that we were only able to observe an improvement
over a 9-month period in people with Alzheimer’s disease and that
the longer-term decline trajectory was unaffected, favours the
third and more ‘symptomatic’ of these mechanisms. It should be
borne in mind that we only ascertained ACEI use at the time
of diagnosis and did not attempt to follow up its continuation.
From the same data resource, we have previously reported an
improvement in routinely measured cognitive function during
the first 6–9 months following initiation of acetylcholinesterase
inhibitor medication in dementia.21 All patients included in the
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study reported here were receiving acetylcholinesterase inhibitor
treatment, so that the more marked improvement in MMSE score
trajectories in those also receiving C-ACEIs compared with
patients who did not receive ACEIs cannot be attributed to
cholinesterase inhibition alone. Furthermore, the relative impro‐
vement in patients receiving C-ACEIs compared with those
receiving NC-ACEIs renders a generic effect of hypertension or
antihypertensive treatment less likely, as does the research cited
earlier which has tended to report findings specific to C-ACEIs.
C-ACEIs and acetylcholinesterase inhibitors may therefore have
mutually promoting actions on acetylcholine bioavailability,
and consequently cognitive function, but this requires further
investigation.
There is evidence that certain C-ACEIs (captopril, trandolapril
and ramipril) and NC-ACEIs (enalapril) are associated with
reduced all-cause and cardiovascular mortality from 18% to 40%
among patients with hypertension.43 However, ACEIs have been
found to be associated with an increased risk of mortality in
patients with Alzheimer’s disease compared with those receiving
angiotensin II receptor blockers or other antihypertensives and also
shown that initial protective effect of ACEIs was disappeared
after adjusting for protopathic bias.29 In our study we found no
differences in survival between groups, which might possibly be
explained by a balancing of these risk and protective effects.
Regarding strengths of our study, we were able to assemble a
large sample of patients with newly diagnosed Alzheimer’s disease
and homogeneity of the comparison groups, as well as outcome
data availability, was maximised by restricting to people receiving
acetylcholinesterase inhibitor treatment. We were also able to
obtain large numbers of cognitive function recordings and to
follow patients up for 3 years after dementia diagnosis: a sub‐
stantially greater period than most previous studies. Limitations
are principally related to the fact that the data-set was derived from
routine records-derived information rather than a ‘de novo’
research cohort. For example, MMSE scores were a relatively
crude measure of cognitive function, diagnoses were clinical rather
than research quality, and confounding factors were limited by
available data. In addition, the group receiving NC-ACEIs was
relatively small and could not be analysed in detail. Finally, the
classification of centrally and non-centrally active agents was based
predominantly on animal models because human data have been
generally lacking and heterogeneous.33 Although a compound’s
ability to cross the blood–brain barrier largely depends on its size,
charge and lipophilicity, the integrity of the blood–brain barrier
and the dose of the medication are also potentially influential.11
Importantly, all these limitations would be expected to obscure
rather than exaggerate observed associations, and it is noteworthy
that positive findings were still found to be present.
In summary, we found some evidence to support a time-
limited effect of C-ACEIs on the trajectory of cognitive function in
people with Alzheimer’s disease receiving acetylcholinesterase
inhibitor treatment. Visual inspection of the MMSE score trajec-
tories in Fig. 1 suggests that cognitive function in people receiving
C-ACEIs was either stable or improved compared with that at
baseline for around 18 months after diagnosis, compared with
around 9 months in those not receiving ACEIs. Whether this
translates into delayed dependency and other functional outcomes
requires further research, which is also required in order for
C-ACEIs to be considered as treatment in the early stages
of Alzheimer’s dementia.44 As Rygiel has suggested, in clinical
practice, practical suggestions for older people at risk of
dementia that have hypertension or other medical conditions with
indications for ACEIs, could be started on a C-ACEI instead of an
NC-ACEI.44
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